Naloxone: Difference between revisions
ClaireLewis (talk | contribs) |
Benalexander (talk | contribs) (→Opioid toxicity: Added intranasal dosing) |
||
| (10 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: [[Opioid]] antagonists | *Type: [[Opioid]] antagonists, [[antidote]] | ||
*Dosage Forms: | *Dosage Forms: | ||
*Common Trade Names: Narcan | *Common Trade Names: Narcan | ||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Opioid toxicity]]=== | ===[[Opioid toxicity]]=== | ||
*Bolus (May repeat q3min up to max dose 10mg | *Bolus (May repeat q3min up to max dose 10mg) | ||
**Apneic or near-apneic - 2mg IV | **Apneic or near-apneic - 2mg IV | ||
**Opioid-naive with minimal respiratory depression - 0.4mg IV | **Opioid-naive with minimal respiratory depression - 0.4mg IV | ||
| Line 14: | Line 14: | ||
**Step 1: Determine the "wake-up dose" or bolus required to wake the pt | **Step 1: Determine the "wake-up dose" or bolus required to wake the pt | ||
**Step 2: Give 2/3 of the "wake-up dose" per hr; mix in 1L D5W | **Step 2: Give 2/3 of the "wake-up dose" per hr; mix in 1L D5W | ||
*Intranasal | |||
**Pre-mixed nasal spray: 3,4, or 8 mg (1 spray) in one nostril. May repeat q 2-3 minutes if no response | |||
**IV solution: 2 mg (1 mg each nostril using atomizer)<ref>Naloxone. In: ''Lexi-Drugs''. UpToDate Inc; 2025. Accessed September 30, 2025. https://www.uptodate.com/contents/naloxone-drug-information</ref> | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*IV: 0.005 to 0. | *Full reversal (overdose or intoxication) | ||
**IV/IO: 0.1 mg/kg (max 2 mg). Repeat every 2 to 3 minutes as needed | |||
*Titrated correction of respiratory depression from therapeutic opioid | |||
**IV/IM/SUBQ: 0.005 to 0.01mg/kg IV every 2 to 3 minutes as needed to desired degree of reversal | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
*Lactation: insufficient data | *Lactation: insufficient data | ||
*Renal Dosing | *Renal Dosing: No dose adjustment | ||
*Hepatic Dosing: No dose adjustment | |||
*Hepatic Dosing | |||
==Contraindications== | ==Contraindications== | ||
| Line 34: | Line 35: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
*[[Opioid withdrawal]] | *[[Opioid withdrawal]] | ||
*Non-cardiogenic [[pulmonary edema]]<ref>Mechanism for Naloxone-Related Pulmonary Edema in Opiate or Opioid Overdose Reversal. August 2015. EBM Consult. https://www.ebmconsult.com/articles/mechanism-naloxone-related-pulmonary-edema-opiate-opioid-overdose-reversal.</ref> | |||
*Serious complications are rare | *Serious complications are rare | ||
==Pharmacology== | ==Pharmacology== | ||
*Metabolism: hepatic | |||
*Metabolism: | *Excretion: renal | ||
*Excretion: | *Mechanism of Action: opioid antagonist (competes for mu receptor binding sites, displacing opioid) | ||
*Mechanism of Action: | |||
*Onset of action - 1-2min | *Onset of action - 1-2min | ||
*Duration of action - 20-90min ('''may be less than that of the ingested opioid''') | *Duration of action - 20-90min ('''may be less than that of the ingested opioid''') | ||
*For this reason many hospital algorithms call for ~3 hours of ED observation prior to discharge | |||
*Some small studies have called for decreasing this time frame to 1 hour but there are often adverse events in a significant proportion of these patients (one study showed that 15% of patients had adverse events such as need for supplemental oxygen after attempting discharge at 1 hour)<ref>Hospital Observation Upon Reversal (HOUR) With Naloxone: A Prospective Clinical Prediction Rule Validation Study Clemency, B.M., et al, Acad Emerg Med 26(1):7, January 2019</ref>. | |||
==See Also== | ==See Also== | ||
*[[Opioid toxicity]] | |||
*[[Opioid withdrawal]] | |||
==References== | ==References== | ||
<references/> | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Toxicology]] | |||
Latest revision as of 23:19, 30 September 2025
General
Adult Dosing
Opioid toxicity
- Bolus (May repeat q3min up to max dose 10mg)
- Apneic or near-apneic - 2mg IV
- Opioid-naive with minimal respiratory depression - 0.4mg IV
- Opioid-dependent with minimal respiratory depression - 0.05mg IV
- Infusion
- Only give if the patient responded to the bolus and required repeat administration
- Step 1: Determine the "wake-up dose" or bolus required to wake the pt
- Step 2: Give 2/3 of the "wake-up dose" per hr; mix in 1L D5W
- Intranasal
- Pre-mixed nasal spray: 3,4, or 8 mg (1 spray) in one nostril. May repeat q 2-3 minutes if no response
- IV solution: 2 mg (1 mg each nostril using atomizer)[1]
Pediatric Dosing
- Full reversal (overdose or intoxication)
- IV/IO: 0.1 mg/kg (max 2 mg). Repeat every 2 to 3 minutes as needed
- Titrated correction of respiratory depression from therapeutic opioid
- IV/IM/SUBQ: 0.005 to 0.01mg/kg IV every 2 to 3 minutes as needed to desired degree of reversal
Special Populations
- Pregnancy Rating: C
- Lactation: insufficient data
- Renal Dosing: No dose adjustment
- Hepatic Dosing: No dose adjustment
Contraindications
- Allergy to class/drug
Adverse Reactions
- Opioid withdrawal
- Non-cardiogenic pulmonary edema[2]
- Serious complications are rare
Pharmacology
- Metabolism: hepatic
- Excretion: renal
- Mechanism of Action: opioid antagonist (competes for mu receptor binding sites, displacing opioid)
- Onset of action - 1-2min
- Duration of action - 20-90min (may be less than that of the ingested opioid)
- For this reason many hospital algorithms call for ~3 hours of ED observation prior to discharge
- Some small studies have called for decreasing this time frame to 1 hour but there are often adverse events in a significant proportion of these patients (one study showed that 15% of patients had adverse events such as need for supplemental oxygen after attempting discharge at 1 hour)[3].
See Also
References
- ↑ Naloxone. In: Lexi-Drugs. UpToDate Inc; 2025. Accessed September 30, 2025. https://www.uptodate.com/contents/naloxone-drug-information
- ↑ Mechanism for Naloxone-Related Pulmonary Edema in Opiate or Opioid Overdose Reversal. August 2015. EBM Consult. https://www.ebmconsult.com/articles/mechanism-naloxone-related-pulmonary-edema-opiate-opioid-overdose-reversal.
- ↑ Hospital Observation Upon Reversal (HOUR) With Naloxone: A Prospective Clinical Prediction Rule Validation Study Clemency, B.M., et al, Acad Emerg Med 26(1):7, January 2019